Patent · US Active

Corticotropin releasing factor receptor antagonists

US11344557B2 · kind B2 · utility

5Cited by

3References

27Claims

0Family size

Assignee

SPRUCE BIOSCIENCES, INC. · US

Inventors

Alexis HOWERTON · San Francisco, US
Hal GERBER · South San Francisco, US
Michael Huang · Ladera Ranch, US

Key dates

Filing date	Oct 5, 2020
Grant date	May 31, 2022
Priority date	—
Expiry date	Oct 5, 2040

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D487/04
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention provides novel pharmaceutical compositions comprising -(4-Chloro-2-(morpholin-4-yl)thiazol-5-yl)-7-(1-ethylpropyl)-2,5-dimethylpyrazolo(1,5-a)pyrimidine and methods of using the same for the treatment of Congenital adrenal hyperplasia (CAH).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.